

1st Quarter of Fiscal 2026 Financial Results and HIV Business Update

August 3, 2026

Shionogi & Co., Ltd.



SHIONOGI

Agenda

1st Quarter of Fiscal 2026 Financial Results **P.3-21**

- 01** **Overview of 1Q FY2026 Financial Results** **(P.3-8)**
- 02** **Progress of Key Businesses** **(P.9-14)**
- 03** **Progress of Development Pipeline** **(P.15-21)**

HIV Business Update **P.22-32**

Overview of 1Q FY2026 Financial Results




SHIONOGI

Significant Growth of Key Businesses

Revenue reached a record high for the first quarter, driven by growth of existing businesses and integration effects from acquired businesses

-Revenue Growth Trend-



Domestic prescription drugs sales: +137.3% (YoY)

- Integration Benefits from Business Investments.
 - **Torii Pharmaceutical, Radicut sales**
- Sales growth of Quviviq

Overseas subsidiaries/exports: +196.6% (YoY)

- Integration and launch of the RADICAVA business in the U.S.**
- Stable growth of cefiderocol in Europe and the United States

Royalty income +25.3% (YoY)

- Revenue growth at ViiV healthcare Ltd.**
- Royalty income related to the former JT pharmaceutical business

Financial Results (Consolidated)

Year-on-year growth achieved revenue and all profit categories

(Unit: B yen)

	FY2026				FY2025	YoY	
	Forecast Full year	Forecast 1H	Apr.-Jun. Results	Achievement (%)	Apr.-Jun. Results	Change (%)	Change
Revenue	700.0	340.0	163.3	48.0	99.8	63.7	63.5
Operating profit	220.0	96.0	66.9	69.7	35.1	90.6	31.8
Profit before tax	220.0	96.0	73.7	76.8	46.3	59.2	27.4
Profit attributable to owners of parent	210.0	108.0	97.7	90.5	39.4	148.2	58.3
EBITDA*1	315.0	152.0	93.4	61.4	40.6	129.8	52.7

Statement of Profit or Loss (Consolidated) (Unit: B yen)

	FY2026		FY2025		YoY	
	Forecast Full year	Forecast 1H	Apr.-Jun. Results	Achievement (%)	Apr.-Jun. Results	Change(%) Change
Revenue	700.0	340.0	163.3	48.0	99.8	63.7 63.5
Cost of Sales	17.1 120.0	18.8 64.0	18.9 30.8	48.1	12.3 12.3	150.0 18.5
Gross profit	580.0	276.0	132.5	48.0	87.5	51.5 45.1
SG&A*1, R&D expenses total	56.4 395.0	57.9 197.0	56.8 92.8	47.1	51.3 51.2	81.2 41.6
SG&A*1	34.3 240.0	34.7 118.0	37.3 61.0	51.7	26.4 26.3	131.8 34.7
R&D expenses	22.1 155.0	23.2 79.0	19.5 31.8	40.2	24.9 24.9	27.7 6.9
Other income & Expenses	35.0	17.0	27.2	159.8	(1.2)	- 28.3
Operating profit	31.4 220.0	28.2 96.0	41.0 66.9	69.7	35.2 35.1	90.6 31.8
Finance income & costs	-	-	6.8	-	11.2	(39.2) (4.4)
Profit before tax	31.4 220.0	28.2 96.0	45.2 73.7	76.8	46.4 46.3	59.2 27.4
Profit attributable to owners of parent	210.0	108.0	97.7	90.5	39.4	148.2 58.3

Main variation factors (YoY)
Revenue Increase: Royalty income, domestic prescription drugs, overseas subsidiaries/exports
Cost of Sales Increase: Sales of Torii Pharmaceutical, one-off expenses related to inventory revaluation of edaravone
SG&A Expenses Increase: Amortization of intangible assets (JT Group pharmaceutical business, edaravone business*2), sales-related expenses of U.S. business, SG&A expenses of Torii Pharmaceutical
R&D Expenses Increase: R&D expenses of the former JT pharmaceutical business and Torii Pharmaceutical
Other Income/Expenses Increase: Share of profit of ViiV Healthcare accounted for using the equity method*2 ※ The impact of PPA associated with Shionogi's increased shareholding in ViiV shares was not reflected in the 1Q
Finance Income/Expenses - Decrease: Change in the accounting treatment of dividends received from ViiV Healthcare*3 - Increase: Foreign exchange gains
Profit Attributable to Owners of Parent Increase: Reduction in tax expense due to the recognition of deferred tax assets

Revenue by Segment

(Unit: B yen)

	FY2026				FY2025	YoY	
	Forecast Full year	Forecast 1H	Apr.-Jun. Results	Achievement (%)	Apr.-Jun. Results	Change(%)	Change
Prescription drugs	178.6	79.9	33.5	42.0	14.1	137.3	19.4
Overseas subsidiaries/export	175.2	85.4	42.2	49.4	14.2	196.6	28.0
Shionogi Inc. (US)	138.7	68.0	32.0	47.1	6.2	417.1	25.8
RADICAVA*	101.7	51.8	24.2	46.7	-	-	24.2
Fetroja	-	-	7.7	-	5.9	29.4	1.7
Shionogi B.V. (EU)	22.6	11.1	6.6	59.7	4.7	40.4	1.9
Fetcroja	-	-	5.0	-	3.4	44.9	1.5
Shionogi China	5.3	2.5	1.5	57.8	1.5	(2.6)	(0.0)
Others	8.7	3.8	2.1	55.2	1.8	15.5	0.3
Contract manufacturing	14.4	7.7	4.0	51.7	4.5	(11.0)	(0.5)
OTC and quasi-drug	18.8	8.3	2.9	34.7	2.4	19.6	0.5
Royalty income	310.6	157.7	80.1	50.8	63.9	25.3	16.2
HIV franchise	276.0	139.1	72.7	52.3	61.2	18.9	11.5
Others	34.6	18.6	7.4	39.6	2.7	169.3	4.6
Others	2.3	0.9	0.6	66.7	0.6	(4.4)	(0.0)
Total	700.0	340.0	163.3	48.0	99.8	63.7	63.5

Main variation factors (YoY)

Prescription drugs

- Increase: Sales of Torii Pharmaceutical, Radicut, Quviviq
- Decrease: Sales of acute respiratory infection drugs

Overseas subsidiaries / Exports

- Increase: RADICAVA, sales of cefiderocol in the U.S. and Europe (U.S.: Fetroja, Europe: Fetcroja)

Royalty income

- Increase: HIV franchise (sales by ViiV Healthcare)
- Other: Royalties related to the former JT pharmaceutical business

1Q Results and Future Outlook

**Steady progress toward achievement of 1H forecast
through further growth of key businesses**

1Q results

Record-high 1Q results for revenue and all profit items

- Performance expanded through growth of key businesses and integration effects from acquired businesses
- Continued investment to drive further growth of the U.S. business

1H outlook

On track to achieve the 1H forecast

- HIV franchise and overseas business expected to continue revenue and profit growth through further expansion
- Advancing initiatives in preparation for a potential increase in COVID-19 infections
- From Q2 onward, the PPA impacts associated with Shionogi's increased shareholding in ViiV will be reflected in "Equity method income."

Progress of Key Businesses




SHIONOGI

Progress of ViiV's HIV Franchise

Long-acting injectable portfolio powers HIV growth and market share increases

ViiV Sales Trend (LAI formulations)



—Treatment—

Revenue (CY2026 2Q)

Growth rate (YoY)

£ **453** M

+ **33** %

- U.S.: **77%** of patients switching to Cabenuva came from competing products



—Prevention—

Revenue (CY2026 2Q)

Growth rate (YoY)



£ **140** M

+ **39** %

Note: Growth is presented at constant exchange rates (CER) and excludes the impact of foreign exchange movements

RADICAVA Business Progress

Achieved record-high 1Q revenue through a smooth business transition and effective PMI*1 execution



U.S. Launch of XOCOVA (Post-Exposure Prophylaxis for COVID-19)

Driving adoption of post-exposure prophylaxis as a new option

Interest in PEP*1 and Physicians' Willingness to Prescribe*2



Individuals at High Risk of Severe Disease

- Approximately **69%** are interested in receiving a prescription for XOCOVA

▶ **92%** of physicians are willing to prescribe



Individuals Living with Someone at High Risk of Severe Disease

- Approximately **81%** are interested in receiving a prescription for XOCOVA

▶ **88%** of physicians are willing to prescribe

Key Ongoing Actions

1



Promoting Awareness and Healthcare-Seeking Behavior

- Prioritized investment in digital channels including social media and CTV*3 to effectively reach high-interest populations
- Use of broadcast TV and search engine optimization to maximize awareness among older adults

2



Promoting Appropriate Use

- Establishment of a sales organization: approximately 160 sales representatives targeting U.S. geographies with high COVID incidence

3



Establishing Distribution & Coverage


- Ensuring pharmacy inventory availability and beginning negotiations with payers for coverage

12 *1 Post-Exposure Prophylaxis: Administration of antiviral agents before symptom onset to prevent development of disease after potential exposure to the virus, such as through contact with an individual infected with COVID-19 *2 Envitalix Consumer and HCP Research (Dec 2024–Mar 2025) *3 Connected TV: Internet-connected video streaming services

Cefiderocol Growth

Maximizing product value through the promotion of appropriate use

Revenue Growth (Europe and U.S.)



Key Achievements and Actions


- **Continued revenue growth**
 - FY2026 1Q Revenue: 12.7 B yen
 - > Europe: YoY + **1.5 B yen (+44.9%)**
 - > U.S.: YoY + **1.7 B yen (+29.4%)**
- **Recognition for efforts to address AMR^{*1}**
 - Ranked No. 2 globally in the Antimicrobial Resistance Benchmark 2026
- **Expansion into the Pediatric Population**
 - Supplemental application accepted for review by the U.S. Food and Drug Administration (FDA)^{*2}
 - > PDUFA target action date: February 23, 2027

Progress in Domestic Business

Diversified product portfolio drives stable growth in the domestic business

Share of domestic business revenue (1Q)

YoY **+19.4B yen** (+137.3%)



Products of Torii Pharmaceutical

1Q revenue: 18.8 B yen*3

- Increased shipment volume of SLIT*4 products*5
- Co-promotion in the dermatology area



Radicut 1Q revenue: 1.8 B yen*6
(Amyotrophic lateral sclerosis (ALS) treatment)

- Encouraging early diagnosis and timely treatment through awareness campaigns



Quviviq (Insomnia treatment)

1Q revenue: 1.5 B yen

- Sales growth driven by increased adoption among psychiatric institutions



Zurzuva (MDD treatment)

1Q revenue: 0.4 B yen

- Growing number of adopting facilities, mainly clinics



Acute respiratory infection (Xocova, Xofluza, Rapiacta)

Rapiacta

- Achieved a 67.5%*7 market share in the COVID-19 treatment market
- Providing information in preparation for infectious disease outbreaks

*1 High social impact QOL-related diseases: sleep disorders, hearing loss, rare pediatric diseases, immunology/allergy, etc. *2 Excluding revenue from Torii Pharmaceutical-related products, Radicut, and Zurzuva *3 YoY growth rate: 13.2% (comparison with the prior-year revenue of Torii-related products in the JT Group pharmaceutical business)*4 SLIT: Sublingual Immunotherapy *5 Although limited shipments remain in place, shipment volumes to wholesalers have been increasing *6 YoY growth rate: 2.4% (comparison with the prior-year revenue at Tanabe Pharma)*7 JAMDAS (Data from April 1 to June 30, 2026)


Progress of Development Pipeline



SHIONOGI

Olorofim: Phase 3 Study Results (Preliminary)

Achievement of the primary endpoint, with regulatory filings planned in Europe and Asia



Treatment Challenges in Invasive Aspergillosis

Treatment options remain limited for patients who cannot receive azole antifungals

Current Treatment Landscape in Invasive Aspergillosis

Patient Population

- Estimated annual diagnoses exceed **200,000** patients across Europe, Japan, and China

High Mortality Risk

- Mortality rate is **100%**^{*1} if left untreated
- Mortality rate is approximately **30%** with current antifungal therapies^{*1}

Lack of Treatment Options

- Azole antifungals are preferred first-line therapy but can be inappropriate due to increasing prevalence of azole-resistant strains,^{*2} drug-drug interactions
- Alternative therapies^{*3} are urgently needed

Expectations for New Alternative Treatment Options




1. Improved Safety Profile

Treatment options that can be more readily used in high-risk patients are needed

Risk of **organ toxicity**

Risk of **drug-drug interactions**



2. Reduced Patient Burden

Need for convenient treatment options that support long-term therapy

Prolonged intravenous treatment

Transition to outpatient care

Contributing to AMR Measures in the Fungal Disease Area

Providing a new treatment option for fungal infections that are difficult to treat with existing therapies

Key Product Attributes of Olorofim

Potent Antifungal Activity

-Active against azole-resistant and rare resistant fungal pathogens*1-

A novel mechanism of action that inhibits pyrimidine biosynthesis, an essential pathway for fungal growth

Favorable Safety Profile

-No major safety concerns identified-

A favorable safety profile that may help reduce patient burden during long-term treatment

An Oral Treatment Option

-A benefit not offered by injectable therapies-

Enabling consistent treatment from hospitalization through discharge

Contributing to AMR measures, a global challenge, as a leading company in infectious diseases

Drug-Resistant Bacteria

Cefiderocol

Severe infections including carbapenem-resistant bacteria

+

Drug-Resistant Fungi

Olorofim

Invasive aspergillosis including azole-resistant strains

*1 Scedosporium, Lomentospora, Scopulariopsis, Coccidioides, etc.

R&D Milestones for FY2026 (Infectious Disease Areas)

Red text: Changes from May 13, 2026, to August 3, 2026, ✓: Milestone achieved

The list of applicable assets is planned to be updated on a rolling basis

Top-line results: This indicates the timing of data acquisition, and the timing of disclosure will be considered separately

Development products	Target diseases	FY2026 1H		FY2026 2H		Target launch timing*1
Ensitrelvir	COVID-19 treatment	Approval (Europe)				-FY2027
	COVID-19 treatment (Pediatric ages 6-11)	Approval (Japan)	✓			
	COVID-19 treatment (Pediatric ages 0-5)			Phase 3 top-line results		
	COVID-19 PEP	Approval (U.S.*2)	✓			
Secutrelvir	COVID-19 treatment (oral)	Phase 3 starts	✓			FY2028-2030
	COVID-19 pre-exposure prophylaxis (injection)			Initiation of Phase 2 IND preparation		FY2031-
S-268024	COVID-19 (JN.1 vaccine)	Approval (Japan)				-FY2027
S-567123	Sarbecovirus*4 infections (Broadly protective coronavirus vaccine)	Phase 1 top-line results		Phase 2 starts		FY2028-2030
S-337395	RSV infections			Phase 2b top-line results		FY2028-2030
Olorofim	Invasive aspergillosis	Phase 3 top-line results	✓	Submission (Europe)		FY2028-2030
Cefiderocol	Pediatric, Gram-negative bacterial infection	Submission (U.S. and Europe)	✓	Approval (U.S.)		-FY2027
S-649228	Gram-negative bacterial infection	Phase 1 top-line results Phase 2 starts				FY2028-2030


R&D Milestones for FY2026 (QOL Disease Areas)

The list of applicable assets is planned to be updated on a rolling basis
Top-line results: This indicates the timing of data acquisition, and the timing of disclosure will be considered separately

Development products	Target diseases	FY2026 1H		FY2026 2H		Target launch timing* ¹
Zatolmilast	Fragile X syndrome			Phase 2 additional analysis results Phase 3 top-line results		FY2028-2030
	Jordan syndrome	Phase 2 top-line results				
S-606001	Pompe disease			Phase 2 LPI		FY2031-
S-054501 (S-600918 + Combination medicine)	Sleep apnea with a central component	Phase 2 top-line results				FY2028-2030
S-054502 (Sulthiame)	Sleep apnea	Phase 1 top-line results Phase 2b/3 starts				FY2028-2030
Redasemtide	Epidermolysis bullosa	Phase 2 top-line results		Submission (Japan)		-FY2027
	Acute ischemic stroke	Phase 2b top-line results				FY2028-2030
Naldemedine	Constipation associated with Parkinson's disease			Phase 2a top-line results		FY2031-
S-531011	Solid tumor	Phase 2 top-line results				FY2031-
SDS-881	Dementia (AI program for cognitive function testing)	Phase 3 top-line results Submission (Japan)				-FY2027

*¹ This indicates the timing of the initial launch in any country or region where SHIONOGI holds commercialization rights, and is not intended to refer to any specific country or region *² LPI: Last Patient In

Integrated R&D pipeline to be unveiled at the R&D Day on November 18, 2026



HIV Business Update



SHIONOGI

Products containing integrase inhibitors licensed by SHIONOGI


ViiV's INSTI¹-based therapies containing dolutegravir or cabotegravir

Approval ²	Formulations	Product name	Approval ²	Formulations	Product name
CY2013	Oral (single agent) Daily	 Tivicay dolutegravir	CY2019	Oral (two-drug regimen) Daily	 Dovato dolutegravir/lamivudine
CY2014	Oral (three-drug regimen) Daily	 Triumeq dolutegravir/abacavir/ lamivudine	CY2021	LAI ³ 6× a year	 CABENUVA cabotegravir; rilpivirine
CY2017	Oral (two-drug regimen) Daily	 Juluca dolutegravir/rilpivirine	CY2021	LAI ³ 6× a year	 Apretude [▼] cabotegravir 200 mg/mL ^{*4}


Integrase Inhibitors Are the Gold Standard for HIV Treatment

Following the launch of dolutegravir, the majority of the market was replaced by integrase inhibitor-based therapies

HIV treatment is now primarily based on combination therapy with 2-3 drugs, including an integrase inhibitor



—Establishing its position as a standard drug in treatment—



^{*1} [Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV \(US DHHS, Sep 12,2024\).](#)



^{*2} [European AIDS Clinical Society \(EACS\) Guidelines. Version 12.1-November 2024.](#)

Sales Growth of ViiV and the Integrase Inhibitor Portfolio

ViiV's growth continues, driven by the integrase inhibitor portfolio


-Regimens with INSTI at the core driving ViiV's growth-

-Integrase inhibitors are among the most widely used drugs globally-



Unmet Needs of People Living with HIV Are Changing

**Since the launch of dolutegravir,
we've seen a shift in the market to focus on quality of life, not just viral suppression**



Creation of LAI Integrase Inhibitor: Cabenuva (6× a year)

No long-acting injectable integrase inhibitors other than ViiV/Shionogi INSTIs projected to be approved until after 2030

—Why was development possible?—

Development of LAI INSTI is highly challenging

Dovato, Juluca

World's first oral two-drug regimen



Confidence that a two-drug regimen is also feasible in LAI formulations



During dolutegravir development

Identification of a compound capable of maintaining sufficient plasma concentration for a long period



Successful early start in LAI drug discovery



—Strengths of cabotegravir—

The only approved long-acting injectable integrase inhibitor



■ **Retains properties comparable to dolutegravir**

- Potent viral suppression
- Low likelihood of resistance emergence



■ **Enables treatment with once-every-two-month dosing**

- Demonstrated sustained antiviral efficacy in clinical trials^{*1}



■ **Robust IP strategy**

- Patent protection into **2040**

LAIs Expected to Drive Growth Beyond 2030

Continued innovation in LAIs positions ViiV to lead the future of the HIV market

-Foundation for ViiV's sustained long-term growth-



Unsolved public health need

Long-acting HIV treatment is the largest growth opportunity



Leading market transformation


With INSTIs at the core; uniquely positioned to shape where the market goes next



Raising standard of care

Long-acting leadership fuels next generation of treatment and prevention options


-Significant near-term growth drivers-



3× a year LAI Treatment (CAB+RPV)

Lowering the dosing frequency of the marketed LAI therapy Cabenuva to enhance convenience

Extending dosing intervals from 6× to 3× a year-



-Development Timeline-

- **CY2026 June** : Phase 3 CUATRO study started
- **CY2028** : Anticipated approval


-Robust IP strategy-

- **Additional patents pending into 2047*3**

2× a year LAI Treatment (VH184+VH499)

Best-in-class profile transforms adherence, setting a new standard of care

-Advancing toward 2× a year LAI treatment-



-Development Timeline-

- **CY2026 H2** : VH499 CINERGY Phase 2b start
- **CY2028** : Phase 3 start


-Robust IP strategy-

- NCE*2 patent expiry into 2040s
- **Patents pending into at least 2047**

CAB (3× a year Prevention)

3× a year Prevention : The optimal choice for patients and healthcare providers

-Extending dosing intervals from 6× to 3× a year-



-Development Timeline-


- **CY2026 H2** : EXTEND 4M pivotal data
- **CY2027** : Anticipated approval

-Robust IP strategy-

- **Patents pending into 2045*⁵**

HIV Market Size (CY2025-CY2035)

HIV market value rapidly shifting from daily orals therapies to LAIs



Appendix

Revenue for Prescription Drugs in Japan

(Unit: B yen)

	FY2026				FY2025	YoY	
	Forecast Full year	Forecast 1H	Apr.-Jun. Results	Achievement (%)	Apr.-Jun. Results	Change (%)	Change
Acute Respiratory Virus Infection drugs	41.6	16.2	0.4	2.3	2.9	(87.2)	(2.5)
Quviviq	6.7	2.9	1.5	52.5	0.1	-	1.4
Zurzuvae	4.0	1.1	0.4	39.1	-	-	0.4
Radicut	7.0	3.5	1.8	50.4	-	-	1.8
Symproic	6.4	3.1	1.7	53.9	1.5	15.0	0.2
OxyContin franchise	4.9	2.5	1.2	48.0	1.1	4.9	0.1
TORII Pharmaceutical-related products*	77.6	36.8	18.8	51.1	-	-	18.8
Other	30.5	13.8	7.8	56.2	8.5	(8.9)	(0.8)
Prescription drugs	178.6	79.9	33.5	42.0	14.1	137.3	19.4

Acute respiratory virus infection drugs

- Anti-SARS-CoV-2 drug: Xocova
- Anti-influenza virus drugs: Xofluza, Rapiacta

***Torii Pharmaceutical-related products**

UP rate: 13.2%

Apr.-Jun. 2026: 18.8 B yen (sales of Torii-related products at SHIONOGI Group)

Apr.-Jun. 2025: 16.6 B yen (sales of Torii-related products at JT Group pharmaceutical business)



Revenue for TORII Pharmaceutical Related Products

(Unit: B yen)


	FY2026				FY2025	YoY	
	Forecast Full year	Forecast 1H	Apr.-Jun. Result* ¹	Achievement (%)	Apr.-Jun. Results* ²	Change (%)	Change
Dermatology Area	23.0	11.1	5.9	53.5	5.5	7.1	0.4
Corectim	9.5	4.9	2.6	53.0	2.5	4.5	0.1
Vtama	4.2	1.6	0.6	38.0	0.7	△14.6	△0.1
Allergen Area・Others	54.6	25.7	12.9	50.1	8.4	52.7	4.4
TORII Pharmaceutical-related products	77.6	36.8	18.8	51.1	16.6	13.2	2.2

FY2026 Exchange Rate

Exchange Rate (Average)		
	FY2026	
	Forecast	Apr.-Jun. Results
USD(\$) – JPY(¥)	153	159.57
GBP(£) – JPY(¥)	205	214.00
EUR(€) – JPY(¥)	184	185.42

Pipeline: Infectious Diseases

as of August 3, 2026




Change from May 13, 2026, to August 3, 2026

- Secutrelvir (Treatment) : Phase 3 initiated
- Cefiderocol (Pediatric) : Submission in US and Europe
- Ensitrelvir (treatment ages 6-11) : Approval in Japan
- Ensitrelvir (PEP) : Approval in US


Pipeline: QOL Diseases with High Social Impact

as of August 3, 2026



Pipeline: QOL Diseases with High Social Impact

as of August 3, 2026




Change from May 13, 2026, to August 3, 2026

- S-229531 : Pre-clinical
- S-213951 : Pre-clinical
- Naldemedine (Opioid-induced Constipation) : Approved in China


Start of the RADICAVA Business in the U.S.

**Leveraging the strengths of the established operating company
to contribute to patients who have not yet gained access**

– Improving Access to Treatment –



–Strengths of RADICAVA Operating Company–



Patient Support in the RADICAVA Business: Three Pillars

Provide comprehensive patient support tailored to each phase from diagnosis through treatment continuation

1

Timely and Reliable Support for Newly Diagnosed Patients



- Raising awareness of the importance of early diagnosis and treatment
- Providing appropriate information to healthcare professionals
- Increasing awareness of RADICAVA among newly diagnosed patients

2


Streamlining Treatment Initiation



- Strengthening proactive and timely patient support
- Reducing time to treatment initiation through faster insurance approvals and seamless pharmacy dispensing
- Enhancing financial support for patients

3

Building a Foundation for Continued Treatment




- Supporting long-term treatment adherence
- Reducing the risk of treatment discontinuation through multiple initiatives
- Providing stage-appropriate support based on data insights

Ensirelvir: Positive Results From the SCORPIO-PEP*1 Trial


Demonstrated the world's first preventive effect against the onset of COVID-19 with an oral antiviral drug*2

-Trial design*3-

Country	US, South America, Africa, Asia including Japan
Trial Design	Multicenter, randomized, placebo-controlled, double-blind trial
Subjects	Family members or cohabitants of COVID-19 patients (approximately 2,400 cases)
Dosing Regimen Sample Size	- Once daily for 5 days (Same as treatment indication) - Ensirelvir: 1,200 cases, placebo: 1,200 cases
Main purpose	Verification of the effect of suppressing the onset of COVID-19 symptoms for 10 days after starting ensirelvir administration



- Phase 3 Trial Results of Ensirelvir (SCORPIO-PEP)-



*1 PEP: Post-Exposure prophylactic *2 [Press release dated October 29, 2024](#)

*3 JRCT: [2031230124](#) *4 The Conference on Retroviruses and Opportunistic Infections

Anti-HIV Drug Released by ViiV

Product name	Formulations	Compounds* ¹	Administrations	Frequency	Indications	CY2025 Sales
Cabenuva	LAI formulations	CAB + RPV	IM injection	Q2M (LA)	Treatment	£ 1,402M
Apretude		CAB	IM injection	Q2M (LA)	PrEP* ²	£ 439M
Dovato	Oral two-drug regimens	DTG + 3TC	Oral	Every day	Treatment	£ 2,678M
Juluca		DTG + RPV	Oral	Every day	Treatment	£ 656M
Tivicay	Oral single agent	DTG	Oral	Every day	Treatment	£ 1,323M
Triumeq	Oral three-drug regimen	DTG+ABC+3TC	Oral	Every day	Treatment	£ 991M

Forward-Looking Statements

- Forecast or target figures in this material are neither official forecasts of earnings and dividends nor guarantee of target, achievement and forecasts, but present the midterm strategies, goals and visions. Official earnings guidance should be referred to in the disclosure of the annual financial report (*kessan tanshin*) in accordance with the rules set by Tokyo Stock Exchange.
- Materials and information provided during this presentation may contain so-called “forward-looking statements”. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements.
- Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, technological advances and patents attained by competitors; challenges inherent in new product development, including completion of clinical trials; claims and concerns about product safety and efficacy; regulatory agency’s examination period, obtaining regulatory approvals; domestic and foreign healthcare reforms; trend toward managed care and healthcare cost containment; and governmental laws and regulations affecting domestic and foreign operations.
- For products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials, and failure to gain market acceptance.
- Shionogi disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
- This material is presented to inform stakeholders of the views of Shionogi's management but should not be relied on solely in making investment and other decisions.
- You should rely on your own independent examination of us before investing in any securities issued by our company. Shionogi shall accept no responsibility or liability for damage or loss caused by any error, inaccuracy, misunderstanding or changes of target figures or any other use of this material.
- This English presentation was translated from the original Japanese version. In the event of any inconsistency between the statements in the two versions, the statements in the Japanese version shall prevail.